Enzastaurin (LY317615.HCl) is currently in a phase III registration trial for diffuse large B-Cell lymphoma and numerous phase II clinical trials. Enzastaurin suppresses angiogenesis and induces apoptosis in multiple human tumor cell lines by inhibiting protein kinase C (PKC) and phosphoinositide 3-kinase (PI3K)/AKT pathway signaling. PI3K/AKT pathway signaling liberates eukaryotic translation initiation factor 4E (eIF4E) through the hierarchical phosphorylation of eIF4E binding proteins (4E-BP). When hypophosphorylated, 4E-BPs associate with eIF4E, preventing eIF4E from binding eIF4G, blocking the formation of the eIF4F translation initiation complex. Herein, we show that enzastaurin treatment impacts signaling throughout the AKT/mTOR pathway leading to hypophosphorylation of 4E-BP1 in cancer cells of diverse lineages (glioblastoma, colon carcinoma, and B-cell lymphoma). Accordingly, enzastaurin treatment increases the amount of eIF4E bound to 4E-BP1 and decreases association of eIF4E with eIF4G, thereby reducing eIF4F translation initiation complex levels. We therefore chose to evaluate whether this effect on 4E-BP1 was involved in enzastaurin-induced apoptosis. Remarkably, enzastaurin-induced apoptosis was blocked in cancer cells depleted of 4E-BP1 by siRNAs, or in 4EBP1/2 knockout murine embryonic fibroblasts cells. Furthermore, eIF4E expression was increased and 4E-BP1 expression was decreased in cancer cells selected for reduced sensitivity to enzastaurininduced apoptosis. These data highlight the importance of modulating 4E-BP1 function, and eIF4F complex levels, in the direct antitumor effect of enzastaurin and suggest that 4E-BP1 function may serve as a promising determinant of enzastaurin activity.
Introduction
Enzastaurin (LY317615.HCl) is an orally available acyclic bisindolylmaleimide currently being evaluated in a phase III registration trial for diffuse large B-cell lymphoma (DLBCL). Enzastaurin is also in multiple phase II proof-of-concept trials as a single agent and in combination with standard oncolytics and targeted therapies. Enzastaurin has been shown to suppress signaling through the phosphoinositide 3-kinase (PI3K)/AKT pathway, blocking the phosphorylation of AKT, glycogen synthase kinase (GSK3b), and ribosomal protein S6 (rpS6; rev. 1). Consequently, enzastaurin directly induces tumor cell death and blocks angiogenesis, with the phosphorylation of GSK3b currently serving as a reliable in vitro and in vivo pharmacodynamic marker (1, 2) .
The eukaryotic translation initiation factor 4F (eIF4F) complex (composed of the mRNA cap-binding protein eIF4E, the scaffolding protein eIF4G, and the RNA helicase eIF4A) is responsible for initiating cap-dependent mRNA translation. eIF4E availability serves as the ratelimiting step in eIF4F complex formation and is largely dependent on binding to its negative regulators, the eIF4E binding proteins (4E-BP; refs. 3, 4) . The hierarchical phosphorylation of the 4E-BPs by mTOR, which directly phosphorylates 4E-BP1 at residues T37/46, S65, and T70, liberates eIF4E (5) . Once released from the 4E-BPs, eIF4E can engage eIF4G, promoting eIF4F complex assembly and enabling mRNA translation (6, 7) . In addition to 4E-BP1 phosphorylation, mTOR also activates the S6 kinases to phosphorylate rpS6. Recent data, however, indicate that rpS6 phosphorylation is dispensable for lymphomagenesis, highlighting the role for the 4E-BP1: eIF4E interaction in malignant progression (8) .
Experimental data indicate that eIF4E has a functional role in cellular transformation, tumor growth, and malignancy by selectively and disproportionately affecting the translation of mRNAs encoding key malignancy-related proteins including VEGF, c-myc, and cyclin D1 (6, 7) . Clinical tissue studies indicate that eIF4E is overexpressed in tumor versus normal tissues and is related to disease progression and reduced patient survival in a variety of cancers including prostate (9) , lung adenocarcinoma (10), gastric (11) , breast (12) , head and neck (13) , and others (7) . eIF4E activity is attenuated by binding to the 4E-BPs. Experimental models show that the 4E-BPs are involved in tumorigenesis (14) (15) (16) and that 4E-BP1 overexpression suppresses tumor formation and growth (17, 18) . Additionally, clinical data indicate increased phosphorylation of 4E-BP1 is associated with disease progression and poor patient survival in prostate (9) , breast (19) , and ovarian (20) cancers. Collectively, these data reveal that activation of eIF4E (either by direct overexpression or release from the 4E-BPs) promotes tumor formation and malignancy in experimental models and is related to reduced patient survival in numerous human cancers. Accordingly, 4E-BP1 has recently been shown to play a crucial role in transformation and that targeting eIF4E or the eIF4F complex provides an attractive, novel anticancer strategy (21) (22) (23) (24) .
We sought to understand more fully the critical determinants for the anticancer activity of enzastaurin. We now show that enzastaurin inhibits multiple phosphorylation events in the AKT/mTOR pathway leading to the hypophosphorylation of 4E-BP1. Consequently, enzastaurin increases the binding of eIF4E to 4E-BP1 and decreases the association of eIF4E with eIF4G. These data indicate enzastaurin treatment reduces the levels of the eIF4F translation initiation complex. Moreover, eIF4E expression is upregulated and 4E-BP1 expression is downregulated in cells selected for reduced sensitivity to enzastaurin-induced apoptosis. Importantly, 4E-BP1 reduction or 4E-BP1/2 knockout blocks enzastaurininduced apoptosis. These data indicate that the modulation of 4E-BP is functionally important for enzastaurininduced apoptosis and may serve as a critical determinant of enzastaurin activity.
Material and Methods
Cell culture 4E-BP1 and 4E-BP2 knockout (4E-BP1/2 KO) and wild-type (4E-BP1/2 WT) murine embryonic fibroblasts (MEF) were derived as previously described (14, 25) . CRL2611 human glioma cells, HCT116 human colon cancer cells, and Farage B-cell lymphoma cells were obtained from the American Type Culture Collection. Cells lines were tested for mycoplasma and other pathogens and were authenticated using short tandem repeat genotyping in accordance with the referenced American Type Culture Collection genotype when available. CRL2611 and MEF cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Gibco, 11995) supplemented with 10% heat inactivated fetal bovine serum (HI FBS; Gibco, 10082). HCT116 cells were maintained in McCoy's 5A media supplemented with 10% HI FBS, 5% sodium pyruvate (Gibco, 11360), 5% sodium bicarbonate (Gibco, 25080), and 5% D-(þ)-glucose (Sigma Aldrich, G8769). Farage B cells were maintained in RPMI-1640 media supplemented with 10% HI FBS, 5% sodium pyruvate (Gibco, 11360), 5% sodium bicarbonate (Gibco, 25080), and 5% D-(þ)-glucose (Sigma Aldrich, G8769). Cells were routinely treated in media with 1% HI FBS as indicated (1) . HCT116 cells were maintained in McCoy's 5A media supplemented with 1% HI FBS and 1 mmol/L enzastaurin for more than 100 passages to select for cells with reduced sensitivity to enzastaurin-induced apoptosis.
Western blotting
Western blots were done as previously described (1) . The antibodies to 4E-BP1, p4E-BP1 Thr37/46 , p4E-BP1 Ser65 , p4E-BP1 Thr70 , AKT Ser473 , AKT Thr308 , eIF4G, mTOR, pMTOR Ser2448 were used at 1:500 dilution (Cell Signaling), eIF4E and AKT were used at 1:500 dilution (BD Biosciences), b-actin at 1:20,000 dilution (Sigma Aldrich). All Western blots were incubated in 5% BSA in Tris-buffered saline Tween-20 (TBST) with 0.1% Tween-20. Secondary antibodies were used at 1:5,000 dilution (Santa Cruz) and incubated in 5% milk and 0.1% Tween-20 in PBS. 7-Methyl-GTP-sepharose (m7GTP) chromatography was used to assess the interaction of eIF4E with either eIF4G or 4E-BP1 from cell extracts as described (9) .
siRNA transfection
A total of 1,000 cells (CRL2611 or HCT116) was plated in 96-well poly-D-lysine plates (Becton Dickinson) and transfected with 5 to 20 nmol/L 4E-BP1 siRNA (Ambion, s223471), 20nmol/L pooled Dharmacon ON-target plus Duplex 4E-BP1 siRNA (J-003005- 11, 12, 13, 14) , or negative control siRNA no. 2 (AM4637, Ambion) in Oligofectamine (Invitrogen, 12252-011). Transfections were carried out in 100 mL DMEM 11995 for CRL2611 cells or McCoy's 5A supplemented with 1% FBS for HCT116 cells for 72 hours. After the 72 hour transfection, 100 mL of 2x dimethyl sulfoxide (DMSO) or enzastaurin was added for 48 to 72 hours.
Apoptosis assays
Induction of apoptosis was measured by oligonucleosomal fragmentation for 48 to 72 hours as indicated (Cell Death Detection Elisa; Roche Applied Science) or by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining for 48 hours, as described (1) . Absorbance values were normalized to DMSO controls (error bars represent AESEM).
Results and Discussion

Enzastaurin suppresses AKT/mTOR pathway phosphorylation
Enzastaurin inhibits signaling through the PKCb and PI3K/AKT pathways specifically blocking the phosphorylation of GSK3b, rpS6, and AKT (1) . We sought to determine to what extent enzastaurin treatment Enzastaurin-Induced Apoptosis Requires 4E-BP1 www.aacrjournals.org would inhibit signaling throughout this pathway in cancer cell lines representing diverse cellular lineages (colon carcinoma, glioma, B-cell lymphoma). The chosen clinical dose for enzastaurin (500 or 525 mg per day) routinely yields 3 mmol/L mean plasma concentrations of total drug, reaching 8 mmol/L in some patients (26, 27) . We therefore evaluated enzastaurin at 1 to 4 mmol/ L. At 16 and 24 hours, enzastaurin suppressed the phosphorylation of rpS6 Ser240/244 , AKT Ser473 , and AKT Thr308 in HCT116 (Fig. 1A) . This reduction in rpS6 Ser240/244 , AKT Ser473 , and AKT Thr308 phosphorylation was also observed in the glioma cell line CRL2611 ( Fig. 1B) and in B-cell Farage lymphoma cells (Fig. 1C ) with the greatest reduction evident at 24 hours. We further observed dose-dependent inhibition of mTOR-Ser2448 , p70S6K Thr389 , 4E-BP1 Thr37/46 , 4E-BP1 Ser65 , and 4E-BP1 Thr70 in all 3 cell lines ( Fig. 1A-C) . These data highlight the inhibitory effect of enzastaurin on the phosphorylation of multiple proteins throughout the PI3K/AKT pathway confirming and extending previously published results (1) .
Enzastaurin reduces the levels of the eIF4F translation initiation complex
Enzastaurin inhibits 4E-BP1 phosphorylation at multiple phosphorylation sites including T37/46, S65, and T70 ( Fig. 1A-C ). As the hypophosphorylation of 4E-BP1 increases the binding of 4E-BP1 to eIF4E (5), we sought to determine whether enzastaurin would increase this association using m7GTP cap analog beads to capture eIF4E and to pull down associated proteins. Enzastaurin treatment substantially increased the amount of 4E-BP1 bound to eIF4E in all 3 cell lines at all concentration levels [ Fig. 2A (inset) , B (left), and C (left)]. To confirm that this increased binding was not a reflection of changes in total eIF4E or 4E-BP1 levels we analyzed total levels of eIF4E and 4E-BP1 [ Fig. 2B (right) and C (right)].
Hypophosphorylated 4E-BPs compete with eIF4G for a mutually exclusive binding site on eIF4E (3, 4) . We therefore examined whether enzastaurin would affect eIF4G: eIF4E binding. Enzastaurin treatment decreased, in a dose-related manner, the amount of eIF4G associated with eIF4E in all 3 lines [ Fig. 2A (inset) , B (left), and C (left)]. Total eIF4G levels were unchanged [ Fig. 2B (right) and C (right)]. These data show that enzastaurin treatment, by promoting the hypophosphorylation of 4E-BP1, sequesters eIF4E from eIF4G, thereby diminishing eIF4F complex levels. To quantify this reduction, we normalized the levels of cocaptured 4E-BP1 and eIF4G to eIF4E and then divided the normalized eIF4G values by the normalized 4E-BP1 values after m7GTP cocapture in HCT116 cells at 8, 16, and 24 hours. These data graphically illustrate the time-dependent reduction in eIF4F levels after enzastaurin treatment ( Fig. 2A) . We next sought to determine whether selection for decreased sensitivity to enzastaurin might involve alterations in eIF4E or 4E-BP1. Indeed, HCT116 cells selected for reduced sensitivity to enzastaurin-induced apoptosis showed increased eIF4E expression and decreased 4E-BP1 expression ( Fig. 2D) .
Reducing 4E-BP1 expression suppresses enzastaurin-induced apoptosis
Enzastaurin induces apoptosis in a wide variety of human cancer cell lines including glioblastoma multiforme (1, 28) , cutaneous T-cell lymphoma (29) , colon (1), gastric (30) , multiple myeloma (31, 32) , and Waldenstrom's macroglobulinemia (33) . Our data indicate that enzastaurin treatment blocks 4E-BP1 phosphorylation and increases the association of eIF4E with 4E-BP1. We therefore examined whether manipulating 4E-BP1 levels would impact enzastaurin-induced apoptosis. Total 4E-BP1 expression was reduced 70% to 80%, 72 hours after 4E-BP1 siRNA transfection in HCT116 and CRL2611 cells (Fig. 3A) . Enzastaurin was added after 4E-BP1 knockdown and assayed for the induction of apoptosis by oligonucleosomal fragmentation 48 to 72 hours thereafter. Apoptosis was evident in both HCT116 and CRL2611 cells treated for 48 hours with 1 to 2mmol/L enzastaurin, a concentration routinely achieved clinically [ Fig. 3B (black To address the potential off-target effects of 4E-BP1 siRNA transfection and to confirm and extend these siRNA data, we also sought to determine whether complete knockout of 4E-BP1 and 4E-BP2 (4E-BP1/2 KO) would affect apoptosis and eIF4F complex levels after enzastaurin treatment. In wild-type (4E-BP1/2 WT) MEFs, enzastaurin-induced apoptosis (Fig. 4A , black bars) and increased the association of 4E-BPs with eIF4E, concomitant with 4E-BP hypophosphorylation (Fig. 4B ). By contrast, in the 4E-BP1/2 knockout (4E-BP1 KO) MEFs, enzastaurin-induced apoptosis was blocked ( Fig. 4A, white bars) . To quantify the reduction in eIF4F complex levels, we normalized the levels of cocaptured 4E-BP1 and eIF4G to eIF4E and then divided the normalized eIF4G values by the normalized 4E-BP1 (Fig. 4C) . The 4E-BP1/2 KO MEFs showed higher eIF4F assembly (i.e., eIF4G bound to eIF4E) than the 4E-BP1/2 WT MEFs. Further, the 4E-BP1/2 MEFs showed dosedependent reduction of eIF4F levels after enzastaurin treatment (Fig. 4C) . These data, along with the 4E-BP1 siRNA depletion data in cancer cells, further support a functional role for the 4E-BPs in enzastaurin-induced apoptosis.
Enzastaurin was originally advanced into the clinic as an antiangiogenic therapy and has subsequently been shown to induce apoptosis directly in cancer cells (1) . The data in this article represent a continued effort to understand the critical effectors for the anticancer effect of enzastaurin. These data confirm and extend previously published data showing that enzastaurin inhibits multiple, key phosphorylation events throughout the PI3K/AKT pathway impacting phosphorylation not only of GSK3b, rpS6, and AKT (1) but also of mTOR, p70S6K, and 4E-BP1. These data show that, by augment- Figure 4 . 4E-BP1/2 knockout increases eIF4F complex levels and reduces enzastaurin-induced apoptosis. Wild-type (WT) and 4E-BP1/2 knockout (KO) murine embryonic fibroblasts were incubated with 1 to 2 mmol/L enzastaurin in media supplemented with 1% HI FBS. A, apoptosis was determined 72 hours after enzastaurin treatment using the Cell Death Detection ELISA (Roche Applied Science). Graph represents mean (AESEM); *, P < 0.05 by unpaired t test. B, Western blot analyses from m7GTP pull-down lysates were done for total eIF4E and 4E-BP1 after 24 hours enzastaurin treatment. C, graph represents eIF4G normalized to eIF4E divided by 4E-BP1 normalized to eIF4E [(eIF4G/eIF4E)/(4E-BP1/eIF4E)]. Data represent mean of 3 separate experiments (AESEM).
